Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 22, 2026.

Answering the ultimate question “What is the Proximal Cause of Aging?”

Mikhail V. Blagosklonny

Aging · 2012 · Review

doi:10.18632/aging.100525

Abstract

Recent discoveries suggest that aging is neither driven by accumulation of molecular damage of any cause, nor by random damage of any kind. Some predictions of a new theory, quasi-programmed hyperfunction, have already been confirmed and a clinically-available drug slows aging and delays diseases in animals. The relationship between diseases and aging becomes easily apparent. Yet, the essence of aging turns out to be so startling that the theory cannot be instantly accepted and any possible arguments are raised for its disposal. I discuss that these arguments actually support a new theory. Are any questions remaining? And might accumulation of molecular damage still play a peculiar role in aging?

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

It is commonly believed that aging is caused by random accumulation of molecular damage due to failure of maintenance, because repair is costly. As emphasized by Kirkwood, “the aging process is caused by the gradual buildup of a huge number of individually tiny faults - some damage to a DNA strand here, a deranged protein molecule there, and so on”. The view is very logical, intuitive and simple. As argued recently, the scholastic philosopher William of Ockham would surely have liked it. Yet, the damage/repair theory leads to incorrect predictions and to bizarre paradoxes. Also, the free radical version of this theory has not been confirmed. After all, William of Ockham lived before Galileo. Now we know that a theory must make correct predictions and be useful, rather than just be elegant.

What if aging is not caused by accumulation of molecular damage? What if random accumulation of molecular damage is irrelevant to aging? Then the cause of molecular damage is not really important. What if aging does not start from day one. In fact, the mortality rate is lower in 10-years old children than in infants. So the period of growth is hardly aging. But when developmental growth is finished, growth-signaling pathways may continue to run on inertia (Fig. 1). Where would that lead the soma?

The hyperfunction theory

In cell culture, when actual proliferation is blocked, then still active growth-signaling and nutrient-sensing pathways such as the TOR (Target of Rapamycin) pathway cause senescence. TOR can convert quiescent cells into senescent cells without any involvement of molecular damage. The TOR pathway is involved in yeast and organismal aging from worm to mammals as well as in age-related disease in mammals. The same pathway, which drives developmental growth, later drives aging and its associated diseases. As discussed in detail previously, aging is of course not a program, but it is a quasi-program, a useless and unintentional continuation (or run on) of developmental programs. Similarly, cellular senescence is a continuation of cellular growth. In brief, over-stimulation leads to increased functions. Such functions include secretion by fibroblasts, contraction by arterial smooth muscle cells (SMC), aggregation by platelets, bone resorption by osteoclasts, lipogeneisis by fat cells, glycogenesis by liver cells, inflammation by neutrophils, phagocytosis by macrophages and so on and so one. Also, overstimulation may render cell signal resistance due to feedback block of signaling pathways. In turn, hyperfunction coupled with signal-resistance causes loss of homeostasis, diseases, organ damage and eventually death of the organism. For example, taken together, hyperfunctions of arterial smooth muscle cells, macrophages, hepatocytes, fat cells, blood platelets, neurons and glial cells, fibroblasts, beta-cells cause organ hypertrophy and fibrosis, atherosclerosis and hypertension (and their complications such as stroke and infarction), osteoporosis and (as complication, born rupture), age-related blindness, gangrenes, renal and heart failure and even cancer. There is no ARD that cannot be linked to initial cellular hyperfunction, in part, driven by mTOR. The senescence-associated secretory phenotype (SASP) is a characteristic hyperfunction of fibroblasts (and some other cells) caused by hyper-mitogenic stimulation of arrested cells. Chronic inflammation, a classic example of hyperfunction, is associated with aging and age-related diseases. Even telomere shortening can also be viewed as a consequence of hyperfunction insofar as it is promoted by hyper-proliferation, and perhaps, therefore, is associated with accelerated age-related diseases (ARD). Although loss of functions is often in terminal aging, loss of function always results from initial hyperfunction (and no another example could be found. This is also applicable to simple multicellular organisms such as Drosophila and C. Elegans.

Given that cellular hyperfunction is one of the main characteristics of aging, David Gems, Yila de la Guardia and Linda Partridge suggested a short name “hyperfunction theory”, which I will use here.

Many predictions of the hyperfunction theory have already been confirmed. Pro-aging signal-transduction pathways and potential anti-aging agents that target them have been revealed, including several existing drugs such as rapamycin and metformin. Moreover, inhibition of hyperfunction in downstream processes regulated by aging pathways, e.g. attenuation of protein synthesis, extends lifespan. Intriguingly, some anti-hypertensive drugs “calm down” hyper-functional signaling-pathways, simultaneously preventing other age-related diseases such as cancer (see for references). Examples include inhibitors of beta-adrenergic as well as of angiotensin II signaling, which are both linked to mTOR signaling. Metformin, an anti-diabetic drug, which indirectly inhibits the mTOR pathway, decreases cancer incidence, prevents premature menopause and increases lifespan in rodents. Rapamycin not only delays typical age-related diseases in animal models but also extends life span in mice. Thus, there exists the opportunity to extend both health span and lifespan in our life time.

The molecular damage theory dies hard

But what about the molecular damage? It was assumed that molecular damage contributes to aging because it accumulates with time. Well, over time you may accumulate money in your bank account. However, neither accumulation of molecular damage nor accumulation of money is a cause of your aging. Yes, molecular damage must accumulate. But although molecular damage accumulates, it does not necessarily limit lifespan, particularly if other causes limit life span. By analogy, if everyone died from accidents, starvation and infection early in life, then aging and age-related diseases (such as obesity and atherosclerosis) would not even be known. By the same token, “aging” due to molecular damage will not manifest itself, if aging due to hyperfunction invariably limits life span. Notably, as a marker of hyperfunction in senescent cells, DNA damage response-signaling pathways can be hyper-activated even without DNA damage.

The hyperfunction theory suggests that repair of molecular damage is important for long life, exactly because it is harmful from day one. But the importance of any process for viability does not imply its role in aging. For example, although DNA replication is important, it (or its abnormalities) does not drive aging. Nonetheless, with a few exceptions, most gerontologists cannot let go of the damage accumulation theory, historically the dominant paradigm in the field. This outlook is superbly expressed by Piotr Zimniak, who argues that the molecular damage theory cannot be replaced by the hyperfunction theory He has briefly summarized the hyperfunction theory in figures 1 A (here figure 1A). First, I will extend figure 2 from A to B (Fig. 2 A,B) in part because the terms “loss of homeostasis” and “age-related diseases” are manifestations of aging either according to molecular-damage or to hyperfunction theories, retrospectively. “Loss of homeostasis” and “age-related diseases” are not alternatives, but instead overlapping terms, almost synonyms, closely related phenomena.

Loss of homeostasis and age-related disease and death

Cellular hyper-function (and secondary signal resistance) must cause loss of homeostasis and, eventually, organ damage and death. Loss of homeostasis encompasses pre-diseases (e.g., glucose intolerance or insulin-resistance), syndromes such as metabolic and diseases such as hypertension, obesity, diabetes, atherosclerosis, renal and cardiac failure and so on. Obesity, hypertension, hyperlipidemia, hyperglycemia, hyperinsulinemia, hyperprolactinemia (and other hypers) are all systemic hyperfunctions, measurable by standard medical methods. They are systemic manifestations of cellular hyperfunction. Such systemic hyperfunctions also constitute loss of homeostasis.

Yet, given my medical background, I prefer the term “disease” to “loss of homeostasis”. Otherwise patients with blindness due to diabetes and patients with stroke due to hypertension and atherosclerosis would both be just suffering from loss of homeostasis. Second, dividing “loss of homeostasis” into specific diseases allows us to better apply the wealth of biomedical knowledge. It is known in detail how hyperfunctions such as an increased lipogenesis by fat and liver cells, hyper-aggregation of platelets, increased contractility and hypertrophy of arterial smooth muscle cells, migration and phagocytosis by macrophages - after many steps that are very well-known in pathology and medicine – cause, for example, damage to the brain via stroke. The sequence of events from TOR-driven hyperfunction to atherosclerosis, type II diabetes and menopause were recently discussed or will be discussed soon.

Age-related diseases (ARD), or if you prefer “loss of homeostasis (LOH)” limit lifespan in protected environments. ARD can be delayed by slowing down aging due to deactivation of the mTOR pathway by calorie restriction, genetic manipulation and drugs. The incidence of age-related diseases increases exponentially with aging. ARD include cancer, hypertension, atherosclerosis, diabetes type II, osteoporosis, sarcopenia, Alzheimer and Parkinson diseases, macular degeneration, organ fibrosis and hypertrophy and many more. Their complications (and often an immediate cause of death) include stroke, infarction, ventricular fibrillation, complications of diabetes such as renal failure, and so on. Also, menopause (in females) and presbyopia are normal age-related diseases, whose incidence does not increase indefinitely since almost all are affected by age 55 (Fig. 3). And of course “cosmetic diseases” such as baldness can be linked to hyper-function too, but this is a topic for another article.

I combine the terms “loss of homeostasis and/or disease” (and call them ADR in this article; may be another term could be malignant hyperfunction or even malfunction). Mild and brief loss of homeostasis is not necessarily called disease but they are not lethal anyway. Some forms of damages such as hip fracture due to osteoporosis are not viewed as loss of homeostasis. Therefore, “and/or” (Fig. 2B). Organ damage or organ malfunctions could occur either early or late in the pathogenesis of ADR. There are positive-feedback loops between cellular hyperfunction and loss of homeostasis as well as vicious cycles between “loss of homeostasis” and “organ damage”. Organ damage is the end point: cardiac arrest and stem brain damage always happen as an immediate cause of death. But all that is well described in the medical literature. All these late and terminal events MUST be the same regardless of either the “molecular damage” or the “hyperfunction theories. In contrast, gerontology is concerned whether it is “molecular damage” or “hyperfunction” cause malfunctions and diseases (causes of death). And the molecular damage theory cannot explain hyperfunctions.

For brevity, I will use the term disease, which include loss of homeostasis (biomedical term) and non-random organ damage (Fig. 2C). Also, TOR causes cellular and system hyperfunctions (e.g., hyperlipidemia and hypertension) are continuation of cellular hyper-functions. Cellular hyperfunction is the essence of cellular aging. The consequence of hyperfunction is the organismal aging, defined as a progressive increase in death rate. Therefore, in figure 1 C, cellular and systemic hyperfunction are combined, as an essence and equivalent of aging, which drives loss of homeostasis, diseases, macro-damage and secondary decline (all combined as “disease” or malfunction in figure 3C).

Finally, TOR-driven hyperfunctions are not only involved in diseases but also in “cosmetic” age-related alterations/diseases. Male pattern of baldness is often associated with hyper-stimulation with testosterone. I will not discuss cosmetic alterations in detail here. Many of them are deadly in some environmental conditions. For example, loss of teeth or vision is deadly in the wild. These are conditional diseases, so I will include them in the term “disease” or ARD.

For complex organisms like mammals the relationships between hyperfunctions (aging), diseases and damage (decline) are: Hyperfunctions (increased cellular functions) including hypertrophy are primary. This is the essence of aging, which silently causes malfunctions and age-related diseases (ADR).Decline of functions, malfunctions and atrophy are secondary. For example, hyper-stimulation of beta-cells by nutrients and mitogens can cause its apoptosis. Here is important to emphasize however that apoptosis can be also a form of hyperfunction, unneeded continuation primary function such as apoptosis during development of the immune system.Damage is caused by aging, not the reverse.Damage is not molecular. It is macro-damage (tissue, system and organ damage), like stroke, infarction, metastases, broken hip fracture and renal failure. Damage may take a form of sudden “catastrophe”, even though hyperfunctional aging slowly generates diseases for decades. If a patient survives infarction (due to medical intervention), she can live for many years, reflecting the fact that catastrophe was not due to the burden of molecular damage. In small organisms (e.g., Drosophila) organ can consist of one cell or even cell's part, but still an organ.

Hyperfunctions (increased cellular functions) including hypertrophy are primary. This is the essence of aging, which silently causes malfunctions and age-related diseases (ADR).

Decline of functions, malfunctions and atrophy are secondary. For example, hyper-stimulation of beta-cells by nutrients and mitogens can cause its apoptosis. Here is important to emphasize however that apoptosis can be also a form of hyperfunction, unneeded continuation primary function such as apoptosis during development of the immune system.

Damage is caused by aging, not the reverse.

Damage is not molecular. It is macro-damage (tissue, system and organ damage), like stroke, infarction, metastases, broken hip fracture and renal failure. Damage may take a form of sudden “catastrophe”, even though hyperfunctional aging slowly generates diseases for decades. If a patient survives infarction (due to medical intervention), she can live for many years, reflecting the fact that catastrophe was not due to the burden of molecular damage. In small organisms (e.g., Drosophila) organ can consist of one cell or even cell's part, but still an organ.

Diseases and organ damage are not random. There is a limited number of common causes of death. This is because hyperfunction is a continuation of develop-mental function, not a random process. Stroke, infarction and cancer are common. Cessation of thrombocytopoiesis (for example) is not. In C elegance and humans, “age-related diseases” are very different of course, because physiology and anatomy is so different. For example, nutrient-sensitive organ (“hypothalamus”) contains 2 neurons only. These two neurons mediate diet-restriction-induced longevity in C. elegans. In all multi-cellular organisms, the rule is: function, then hyperfunction (aging), then mal-function.

Argument 1: As argued by Piotr Zimniak, “I would hesitate to accept that catastrophic events, such as a stroke in a middle-aged person or sepsis in an otherwise healthy individual, are aging”.

Me too. To say that “aging causes diseases” is not to mean that “all diseases are caused by aging”. Clearly, not all diseases are caused by aging. For example, sepsis is caused by microorganisms. Even “age-related” diseases and their complications such as stroke could result from genetic defects, developmental abnormalities, environmental factors and so on. Or stroke could be due to accelerated atherosclerosis and hypertension, which in turn could be due to either accelerated aging, genetic/environmental factors or both. It could be a combination of genetic defects, environmental factors (smoking) and aging, which drives atherosclerosis, platelet hyperfunction and hypertension. For details here, I refer the readers to medical textbooks.

The point is not that age-related diseases are always caused by aging but that aging is sufficient to cause age-related diseases (either organ hyperfunction or its malfunction/failure). Even without genetic predisposition and environmental causes, aging causes stroke and other diseases, which together kill every human being (so far) by the age of 122 (the age at death of the oldest woman, Jeanne Calment). True age-related diseases (ARD) are manifestations and exacerbations of the normal aging process. Any particular ARD (age-related diseases) may not happen in any given individual simply because other ARD can terminate life first (Fig. 4). As we will discuss, time of onset, the frequency and the inevitability of ARD vary because aging is not programmed but an imprecise continuation of development. But here is a second argument against the hyperfunction theory.

Argument 2: Aging kills not by causing catastrophic damage but “-rather loss of homeostasis, i.e., aging, can lower cell/tissue robustness and precipitate catastrophic events”.

In other words, by lowering robustness “accumulation of molecular damage” in the brain would precipitate stroke. This scenario is imaginary. This is not how it happens. Rather hyperfunctions such as hypertension, propensity to thrombosis, rapture of or stenosis by atherosclerotic plaque cause stroke. By analogy, hurricanes cause damage due to their “hyperfunction and robustness”. In contrast, weakness of construction does not precipitate catastrophe in good weather. Let us extend the analogy. An increased use of oil and coal (purposeful program) leads to carbon emissions, which lead to global warming (aimless quasi-program, analogous to hypertension, atherosclerosis and hyper-coagulation), which contribute to other factors that generate a particularly powerful storm, which can be damaging, if it strikes a vital location such as New Orleans (or the brain, in the case of stroke).

Should we re-invent medical science to fit the theory of molecular damage? More plausibly, it is any theory of aging that should reconcile itself with physiology, pathology and medicine, rather than vice versa. Hyperfunction (hypertension, propensity to thrombosis, etc) causes catastrophic events. Even cancer cells, which actually accumulate molecular damage, are robust and in turn damage and kill the organism due to their robustness. Only after non-random system/organ damage, is there decline and weakness. The decline phase is not driven by TOR and is only marginally quasi-programmed, a process run loose. This is a subject for emergency medicine, not gerontology.

Elderly patients who are immobilized by stroke, for example, are vulnerable to infections and sepsis. However, it is not aging per se that provoked sepsis but is rather immobolization caused by stroke (or in other words complications of age-related diseases, which then take their own TOR-independent course). But even then hyperfunctions contribute to deadly outcome such as fatal septic shock, which can be prevented with rapamycin.

Normal and hyper-functions

Hyper-functions result from the continuation (or running on) of normal functions. For example, blood pressure rises from birth to adulthood. This developmental program increases robustness by assuring optimal blood pressure. But its continuation (hyperfunction) leads to hypertension. As another example, at puberty in girls, a carefully-regulated increase of estrogen and gonadotropin levels switch on the reproduction (program, function). A continuation of the same process (quasi-program, hyperfunction) progressively impairs fertility after 30 (Fig. 2) and eventually culminates in ovarian failure and menopause. Then, levels of estrogens drop (decline), accelerating osteoporosis. Menopause is a typical age-related disease. It is not called a disease simply because it happens in all women (Fig. 3). Actually, it does not: some women die before menopause. Just 300 years ago most women died before menopause. Menopause is a quasi-programmed disease. Menopause is particularly program-like, because it happens relatively early in life, when quasi-program (hyperfunction) is still very directional, a precise continuation of the developmental program for reproduction.

I need to emphasize that hyper-function is not always an increased function. It may be unneeded normal function like growth and apoptosis. In analogy, a car that is driving at 65 pmh at small parking lot is “hyperfunctional”, even if at the highway, this speed isr normal. Similarly, the TOR activity that is constantly and chronically at the level of rapidly dividing cells, (“proliferating cell” level) is gerogeni in resting postmitotic cells.

Some facts on age-related diseases (ARD)

Any theory of aging (regardless of the cause of aging) must be in agreement with the following medical facts: The incidence of age-related diseases (ARD) increases exponentially with age in parallel with death rate. This is not co-incidental but rather reflects the fact that ARD cause death. If an individual does not die from one disease (e.g., cancer), he/she will eventually die from another (e.g., stroke and myocardial infarction). Of course, small organisms, which even lack the heart have different ARD, which would be better studied, if these small animals “complain to their “doctors”.Aging kills via diseases. In fact, no one has ever died without a cause. And “natural causes” always denotes disease. In very elderly people, the diagnosis of “death from natural causes” means many competing causes (diseases) simultaneously. Death from natural causes simply excludes death from suicide and homicide. But there is no such medical diagnosis as “death from accumulation of molecular damage”. This “nonexistent diagnosis” is simply not needed because one or several deadly diseases can be always (always) found (unless homicide). Even sudden cardiac death usually results from myocardial fibrillation (archetypical hyper-function of electrical myocytes andventricular hypertrophy).

The incidence of age-related diseases (ARD) increases exponentially with age in parallel with death rate. This is not co-incidental but rather reflects the fact that ARD cause death. If an individual does not die from one disease (e.g., cancer), he/she will eventually die from another (e.g., stroke and myocardial infarction). Of course, small organisms, which even lack the heart have different ARD, which would be better studied, if these small animals “complain to their “doctors”.

Aging kills via diseases. In fact, no one has ever died without a cause. And “natural causes” always denotes disease. In very elderly people, the diagnosis of “death from natural causes” means many competing causes (diseases) simultaneously. Death from natural causes simply excludes death from suicide and homicide. But there is no such medical diagnosis as “death from accumulation of molecular damage”. This “nonexistent diagnosis” is simply not needed because one or several deadly diseases can be always (always) found (unless homicide). Even sudden cardiac death usually results from myocardial fibrillation (archetypical hyper-function of electrical myocytes andventricular hypertrophy).

The later the onset of a disease, the greater the variability in the time of its onset (Fig. 2). This is because aging is not programmed, but quasi-programmed. It is a continuation of development. Development is strictly regulated. But aging and its diseases are not because they are an unintended, non-guided continuation of developmental growth. By analogy, the longer you walk with your eyes closed, the less precisely you continue in the same direction. The further from the end of development, the bigger deviation and the higher imprecision. A particular age-related disease (ARD) could strike at 40 and at 110 and at 300 in some people, if they lived so long). It would strike everyone, if other diseases would not terminate their lives first (Fig. 2). It is perhaps the case that any age-related disease would develop sooner or later in anyone, and only death from other diseases precludes death from any given one.

The time of onset of ARD determines the frequency and inevitability of the disease (Fig. 2). Importantly, this also correlates with the invariability of age of disease in everyone and its precision. Early ARD is a direct continuation of developmental programs. I already mentioned progressive loss of fertility and menopause in women, which is a direct continuation of reproductive function. Another example is presbyopia, a progressive hardening of lens that prevents focusing at close small objects. Symptoms such as problems focusing on fine print, requiring glasses, are noticed between the ages of 40 and 50, very often almost suddenly. This ARD is a quasi-program, a continuation of developmental program. The near point of vision is very close in infants and then progressively moves further away as an organism grows larger. The same process continues later in life: from 7 cm at age 10, to16 cm at age 40, to 100 cm at age 60. Mechanistically, this is hyperfunction due to progressive increase of thickness and stiffness of the crystalline lens as well as continual growth of the lens. Most importantly, a continuation of this quasi-program (quasi-quasi-program) is age-related nuclear cataract, which is a cause of blindness much later in life, involving genetic and environmental factors. Therefore, cataract does not happen to everyone and is variable in its timing of onset.

Argument 3: “it would be difficult to identify catastrophic death events in, for example, bacteria, organisms that also age”.

Yes, I agree of course. If bacteria indeed age, they may age from accumulation of molecular damage, precisely because they do not undergo hyperfunctional aging and have a chance to experience (or not) aging from accumulation of damage. But multicellular organisms do not die from the same “aging” as bacteria. In multicellular organisms, hyperfunctions lead to eventual disintegration of the soma. In contrast bacteria may age from accumulation of moleculer damage (most probable) but they have no multicellular soma and never dir from stroke anyway. Bacteria is irrelevant example of commom aging.

Age-related diseases in worm and flies

Due to extensive biomedical research, humans are the most studied animal. No one dies from “healthy aging”, without a cause: either natural causes such as disease or homicide/suicide. Similar, all mammals die from age-related diseases (ARD), albeit their frequencies vary dramatically. This could be expected given a quasi-programmed nature of aging and ARD. If one disease occurs earlier than other diseases, it will mask all other diseases. Likewise, Pacific Salmon die from quasi-programmed ADR, namely massive organ damage, resulting from continuation of the reproductive program. This is a particular clear example of quasi-programmed hyperfunction. It is often stated that all Pacific Salmon die from aging/ADR, and therefore that this is a program. Not true. Only 1-2% Pacific Salmon die from ADR, all others die earlier from accidental causes, which must be expected in the wild, (see figure 3 in ref.).

Fruit flies and worms die from manifestations of aging or ARD. ADR as causes of death are more specific than vague death from aging. In fruit flies, diseases include neurodegeneration, cardiac dysfunction and even “diabetes”. TOR is involved in age-related pathologies in flies. Insulin, which activates TOR, is implicated in pathologies resembling mammalian metabolic syndrome, diet-induced obesity, diabetes and cardiac dysfunction. As in mammals, high-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway. Thus main pro-aging pathways in Drosophila include insulin/FOXO/TOR, TOR, JNK, NF-kB.

In the nematode worm Caenorhabditis elegans, several “diseases” can be identified, including infections. Many of the diseases of aging seen in worms are consistent with quasi-programmed hyperfunction, and within its short 2-3 week lifespan C. elegans develops a number of pathologies involving extreme hypertrophy. One example, discussed by David Gems and Linda Partridge, involves yolk, which is synthesized in the intestine in large quantities to provision the developing oocytes. After several days of reproduction, reproduction ceases. However, production of yolk continues, and consequently it accumulates in large pools within the body cavity. This accumulation is suppressed in long-lived daf-2 insulin/IGF-1 receptor mutants. Moreover, inhibition of yolk protein gene expression extends worm lifespan, suggesting that quasi-programmed yolk accumulation increases age-related mortality. So worm and fly die from ADR too, just different ADR. Needless to say that even different mammals have different frequency of common ADR. Needless to say that even different nations have different prevalence of ADR.

Argument 4: If aging is quasi-programmed hyper-function, why then is aging associated with decline and atrophy? The critic agrees that “atrophy, a classical sign of aging-related decline, can be in fact secondary to an initial hyperfunction and hypertrophy (Blagosklonny, 2012).” This is correct: “signs of age-related decline” are secondary.

From hyperfunction/hypertrophy to decline/atrophy

There are diverse mechanisms of secondary atrophy during aging.

Quasi-programmed (hyperfunction-driven) apoptosis. In this case, atrophy is secondary to signal resistance due to mTOR overactivation. For example, in insulin-secreting beta-cells overactivated by nutrients and insulin, mTOR causes cellular hypertrophy/hyperplasia/hyperfunction and secondary insensitivity to IGF-1 and deactivation of Akt, leading to beta-cell death. mTOR-dependent hyperfunction and hypertrophy of beta-cells, may eventually culminate in cell loss and decline of function. Similar quasi-programmed apoptosis could be observed in the muscle, the immune system and subcutaneous adipocytes. Apoptosis is programmed in development but quasi-programmed in aging. Also, strong hyper-mitogenic drive can force post-mitotic neurons into the cell cycle leading to apoptosis in Alzheimer disease. Importantly, cellular senescence is associated with both hyper-mitogenic drive and death in mitosis, explaining this phenomenon.

Hyper-stimulation-driven cell exhaustion. For example, mTOR overactivation or growth factor stimulation drives exhaustion of stem cells and ovarian oocytes

Poor wound-healing could be due to signal resistance secondary to cellular aging and hyperglycemia.

Metabolic-self destruction due to hyper-active TOR.

Common atrophy is secondary not to aging itself but to age-related diseases. This is disease-driven atrophy, the end point of some diseases. This is so far away from initial cause that it is completely unrelated to aging and is mTOR-independent. Let me provide two examples. Atherosclerosis of the femoral artery can cause not only atrophy but even gangrene of the feet. Atrophy is very common in ischemia due to atherosclerosis. As another example, hip fracture in an elderly person often leads to prolonged immobilization. Muscle atrophy is secondary to immobilization, which is secondary to the broken hip, which is secondary to osteoporosis, which is secondary to hyperfunction of osteoclasts… and so on. This is disease-driven atrophy. Atrophy is common because it is secondary to diseases. This further supports the thesis that there is no healthy aging (healthy aging is no aging or very slow aging).

Argument 5: When cellular hyperfunction causes atrophy, there must be molecular mechanisms such as interaction of ligand with receptor, protein aggregation and so on. More specifically, the critic claims that “an overproduced ligand may over stimulate or desensitize a receptor” For example, an overproduced ligand may over stimulate or desensitize a receptor, and an overabundant protein may aggregate and interfere with intracellular trafficking, or co-precipitate with and thus withdraw essential cell constituents. First, this is still an example of hyper-function. Importantly, rapamycin alleviates toxicity of different aggregate-prone proteins and decreases aggregate-prone proteinsSecond, this is not molecular damage but signal transduction. In contrast, the molecular damage theory is about life long accumulation (!) of random (!) molecular damage due to failure of repair/maintenance (!). As emphasized by Kirkwood, “the aging process is caused by the gradual buildup of a huge number of individually tiny faults - some damage to a DNA strand here, a deranged protein molecule there, and so on”.

If we redefine “signal transduction” as “accumulation of random molecular damage due to failure of maintenance”, then yes, this is a cause of aging and age-related diseases. Then driven by mTOR, “molecular damage” (formerly, signal transduction) includes protein phosphorylation as well as protein synthesis, inhibition of autophagy and caspase activation. But this is hyperfunction, not failure of maintenance. Phosphorylation of S6K by mTOR, modification of NF-kB or dephosphorylation of Akt, for instance, are not molecular damage. This is signal transduction. Exactly the same signal transduction is involved in development, cell growth, differentiation and apoptosis. These are normal functions. Since the same molecular events are involved in development and developmental growth, this would lead to the reductio ad absurdum that development is caused by damage. More plausibly, their (developmental functions) continuation gives rise to quasi-programmed hyperfunction. These normal functions and hyperfunctions can be inhibited by signal transduction inhibitors including rapamycin.

Life long accumulation of molecular damage is irrelevant to aging. Aging (hyper-function of signaling pathway) causes damage and this damage is organ/system/organismal damage (not molecular damage). Hyperfunction of liver cells, for instance, after several decades, contributes to brain damage via stroke.

Healthy death in molecular damage theory

As commonly depicted, aging (loss of homeostasis), caused by molecular damage, in turn causes death via two independent ways (Fig. 4A). The first way is via an increased susceptibility to diseases. The second way is directly without any diseases, and is the true aging mechanism, according the molecular damage theory. This is incorrect. Consider young healthy constructor worker fall to death from the storm (Yes, this is “healthy” death but not from aging). Another example. The fall from the height of 100 year old person is due to either age-related Parkinson's disease or due to infarction. This is not death from healthy aging. This is death due to an age-related disease.

As we discussed, death from aging is death from diseases (natural causes) (Figs. 5,6). Even the oldest people do not die from healthy aging. There is no such medical diagnosis as healthy death or death from asymptomatic accumulation of molecular damage. Of course, we can consider “loss of homeostasis” broadly, including severe deviations of homeostasis or diseases. But then there is no other “disease pathway” anyway. Regardless of the causes of aging, the causes of death and the path from “loss of homeostasis” to death are well known. In all theories of aging, this must be identical because this is a medical fact (Fig. 5). There is no death directly from healthy aging (of healthy loss of homeostasis). This is a part of the same path (Fig. 5). So, shift from A to B (Fig. 4), exactly as in figure 2 B.

Now the question is how accumulation of molecular damage drives each age-related diseases (Figs. 5, 6). For example, how accumulation of molecular damage causes insulin resistance, hypertension and obesity. There is no obvious answer.

Is TOR-driven hyperfunction true aging?

Is it true aging? Or is it just a process related to disease and mortality? No, it is genuine aging. Not only because it determines mortality (a hallmark of aging is an exponential increase in mortality rate) but also because mTOR-dependent hyperfunctions, signal-resistance, hypertrophy, hypermitogenic drive coupled with loss of regenerative potential are markers of cellular senescence. Cellular senescence can be caused by mTOR activation in cell culture. Although by arresting cell cycle, DNA damage response (DDR) creates conditions for senescence (if mTOR is active), the accumulation of molecular damage itself does not cause senescence in cell culture. In contrast, accumulation of molecular damage contributes to cancer cell immortality. Thus TOR-driven hyperfunction links cellular aging to age-related diseases and organismal aging, defined as an increase of the probability of death.

Do any questions remain unanswered?

Although we have answered most of the issues relating to the damage/maintenance vs hyperfunction debate raised by P. Zimniak (one is left for the conclusion), it may seem that many more unanswered questions remain. Yet, some of them have been answered previously (see PubMed “Blagosklonny” and related references within) and others will be answered in forthcoming articles. The evolutionary aspects, the links between development and aging, pro-aging and anti-aging genes, common signaling pathways that drive aging, cellular senescence and diseases such as cancer have been extensively discussed. According to the hyperfunction theory, aging and its manifestations are never programmed: even menopause and the death of Pacific Salmon are not programmed. Both are excellent examples of quasi-program, a non-adoptive, aimless, harmful continuation of a reproductive program.

Also, as already discussed, lifespan is determined not only by the aging process but also by aging-tolerance, an ability to tolerate disease of aging and their complications. As a matter of fact, almost all medical interventions (including by-pass surgery and teeth proteases) increase aging tolerance rather than slow down aging. When needed, natural selection may favor anatomical and molecular adaptations such as collateral blood vessels and heat shock proteins, for example. Thus extra coronary arteries would increase lifespan despite age-related atherosclerosis, hypertension and thrombosis. Aging-tolerance is a concept that can solve some mysteries of aging. Many potential questions that might be asked are purely medical. Their answers can be found in medical textbooks.

There are a few questions that are difficult to answer now: What TOR-independent pathways contribute to hyperfunctional aging? For example, sirtuins, FOXO, AMPK and IGF-1 can all be linked to the mTOR networks. What about JNK and NF-kB,? Are these pathways TOR-independent? And what are crucial downstream effectors of TOR that control aging?It seems that rapamycin should be used in intermittent fashion, perhaps in combinations with e.g. metformin, lipid-lowering drugs, and beta-blockers and angiotens together with dietary restriction and physical exercise. But what are the exact doses and schedules maximize positive and minimize negative effects?What would be the causes of death if TOR-driven aging were suppressed? Hyperfunction driven by run on of other pathways? Accumulation of molecular damage? Mitochondrial expansion? Other types of unknown aging? Would anti-oxidants become useful for that types of aging? And what are the pathological manifestations of accumulation of random molecular damage?

What TOR-independent pathways contribute to hyperfunctional aging? For example, sirtuins, FOXO, AMPK and IGF-1 can all be linked to the mTOR networks. What about JNK and NF-kB,? Are these pathways TOR-independent? And what are crucial downstream effectors of TOR that control aging?

It seems that rapamycin should be used in intermittent fashion, perhaps in combinations with e.g. metformin, lipid-lowering drugs, and beta-blockers and angiotens together with dietary restriction and physical exercise. But what are the exact doses and schedules maximize positive and minimize negative effects?

What would be the causes of death if TOR-driven aging were suppressed? Hyperfunction driven by run on of other pathways? Accumulation of molecular damage? Mitochondrial expansion? Other types of unknown aging? Would anti-oxidants become useful for that types of aging? And what are the pathological manifestations of accumulation of random molecular damage?

The peculiar role of molecular damage

Repair of random molecular damage is so important that cumulative damage does not reach a deadly threshold during the lifetime. In progeria, fitness is low from day one. There is a very strong natural selection for repair and maintenance. In contrast, mTOR-driven functions are essential early in life and there is a very strong selection for robust mTOR-dependent functions, even if their continuation (hyperfunctions) are harmful in old age. Still, we cannot exclude contribution of molecular damage to some symptoms of aging (Fig.7). This is simply unknown. May it decrease aging-tolerance? This is a fascinating question to answer.

A peculiar case is cancer. Accumulation of damage does not make a cancer cell fragile, arguing against the molecular damage theory, but instead via rounds of selection and proliferation which create robust cells that damage the organism. Notably, such selection of random mutations culminates in non-random activation of the mTOR pathway. Activation of the PI3K/mTOR pathway is the most common alteration (and therapeutic target) in cancer. Also, hyper-activation of the DNA damage response, involving TOR-like kinases, may contribute to hyperfunction. Therefore, molecular damage and autonomous activation of damage-sensing signal-transduction pathways may contribute to hyperfunction, not vice versa.

The last argument for molecular damage theory

The last argument by Zimniak is: “Hyperfunction is one of several sources of molecular damage, on equal footing with reactive metabolites, toxicants, ROS, electrophiles, stochastic events, and many others”. This argument will not be discussed all over again. Not only because hyper-functions are not a source of accumulation of molecular damage. But mostly because the starting point of this article is that the theory of molecular damage did not fit numerous observation, made incorrect predictions, did not contribute to medical advances, and did not lead to any practical application. As philosophers teach us, the theory cannot be wrong (or right), but it can be useless.

References 227

  1. 1.

    Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120:437-447.

    Not in our library10.1016/j.cell.2005.01.027

  2. 2.

    Kirkwood T. Why women live longer. Stress alone does not explain the longevity gap. Sci Am. 2010;303:34-35.

    Not in our library

  3. 3.
  4. 4.

    Blagosklonny MV. Paradoxes of aging. Cell Cycle. 2007;6:2997-3003.

    Not in our library10.4161/cc.6.24.5124

  5. 5.

    Blagosklonny MV. Why the disposable soma theory cannot explain why women live longer and why we age. Aging (Albany NY). 2010;2:884-887.

    Not in our library10.18632/aging.100253

  6. 6.

    Blagosklonny MV. Aging: ROS or TOR. Cell Cycle. 2008;7:3344-3354.

    Not in our library10.4161/cc.7.21.6965

  7. 7.

    Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, Back P, Matscheski A, Vanfleteren JR, Gems D. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev. 2008;22:3236-3241.

    Not in our library10.1101/gad.504808

  8. 8.

    Gems D, Doonan R. Antioxidant defense and aging in C. elegans: Is the oxidative damage theory of aging wrong? Cell Cycle. 2009;8:1681-1687.

    Not in our library10.4161/cc.8.11.8595

  9. 9.
  10. 10.

    Pani G. P66SHC and ageing: ROS and TOR? Aging (Albany NY). 2010;2:514-518.

    Not in our library10.18632/aging.100182

  11. 11.

    Cabreiro F, Ackerman D, Doonan R, Araiz C, Back P, Papp D, Braeckman BP, Gems D. Increased life span from overexpression of superoxide dismutase in Caenorhabditis elegans is not caused by decreased oxidative damage. Free Radic Biol Med. 2011;51:1575-1582.

    Not in our library10.1016/j.freeradbiomed.2011.07.020

  12. 12.

    Lapointe J, Hekimi S. When a theory of aging ages badly. Cell Mol Life Sci. 2009;67:1-8.

    Not in our library10.1007/s00018-009-0138-8

  13. 13.
  14. 14.

    Speakman JR, Selman C. The free-radical damage theory: Accumulating evidence against a simple link of oxidative stress to ageing and lifespan. Bioessays. 2011;33:255-259.

    Not in our library10.1002/bies.201000132

  15. 15.

    Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol Med. 2011;51:327-336.

    Not in our library10.1016/j.freeradbiomed.2011.05.010

  16. 16.

    Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7:3355-3361.

    Not in our library10.4161/cc.7.21.6919

  17. 17.

    Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8:1888-1895.

    Not in our library10.4161/cc.8.12.8606

  18. 18.

    Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle. 2009;8:1896-1900.

    Not in our library10.4161/cc.8.12.8809

  19. 19.

    Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY). 2009;1:1008-1016.

    Not in our library10.18632/aging.100115

  20. 20.

    Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A. 2010;107:9660-9664.

    Not in our library10.1073/pnas.1002298107

  21. 21.

    Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A. 2012;109:13314-13318.

    Not in our library10.1073/pnas.1205690109

  22. 22.
  23. 23.

    Schug TT. mTOR favors senescence over quiescence in p53-arrested cells. Aging (Albany NY). 2010;2:327-328.

    Not in our library10.18632/aging.100164

  24. 24.

    Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY). 2010;2:535-537.

    Not in our library10.18632/aging.100202

  25. 25.

    Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, Fornace AJ, Pospelova TV, Pospelov VA. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle. 2010;9:3945-3955.

    Not in our library10.4161/cc.9.19.13160

  26. 26.

    Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle. 2012;11:2391-2401.

    Not in our library10.4161/cc.20683

  27. 27.

    Pospelova TV, Leontieva OV, Bykova TV, Zubova SG, Pospelov VA, Blagosklonny MV. Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle. 2012;11:2402-2407.

    Not in our library10.4161/cc.20882

  28. 28.
  29. 29.

    Leontieva O, Gudkov A, Blagosklonny M. Weak p53 permits senescence during cell cycle arrest. Cell Cycle. 2010;9:4323-4327.

    Not in our library10.4161/cc.9.21.13584

  30. 30.

    Dulic V. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence? Aging (Albany NY). 2011;3:3-4.

    Not in our library10.18632/aging.100257

  31. 31.

    Maki CG. Decision-making by p53 and mTOR. Aging (Albany NY). 2010;2:324-326.

    Not in our library10.18632/aging.100166

  32. 32.

    Wesierska-Gadek J. mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging. Aging (Albany NY). 2010;2:892-893.

    Not in our library10.18632/aging.100240

  33. 33.

    Serrano M. Shifting senescence into quiescence by turning up p53. Cell Cycle. 2010;9:4256-4257.

    Not in our library10.4161/cc.9.21.13785

  34. 34.

    Lane DP, Verma C, Fang CC. The p53 inducing drug dosage may determine quiescence or senescence. Aging (Albany NY). 2010;2:748.

    Not in our library10.18632/aging.100229

  35. 35.
  36. 36.
  37. 37.

    Stipp D. A new path to longevity. Sci Am. 2012;306:32-39.

    Not in our library10.1038/scientificamerican0112-32

  38. 38.

    Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14:885-890.

    Not in our library10.1016/j.cub.2004.03.059

  39. 39.

    Jia K, Chen D, Riddle DL. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development. 2004;131:3897-3906.

    Not in our library10.1242/dev.01255

  40. 40.

    Kaeberlein M, Powers RWr, Steffen KK, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S, Kennedy BK. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310:1193-1196.

    Not in our library10.1126/science.1115535

  41. 41.

    Ayyadevara S, Alla R, Thaden JJ, Shmookler Reis RJ. Remarkable longevity and stress resistance of nematode PI3K-null mutants. Aging Cell. 2008;7:13-22.

    Not in our library10.1111/j.1474-9726.2007.00348.x

  42. 42.

    Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. The TOR pathway comes of age. Biochim Biophys Acta. 2009;1790:1067-1074.

    Not in our library10.1016/j.bbagen.2009.06.007

  43. 43.

    Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M, Ramadani F, Okkenhaug K, Schuster E, Blanc E, Piper MD, Al-Qassab H, Speakman JR, Carmignac D, Robinson IC, Thornton JM, Gems D, Partridge L, Withers DJ. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 2008;22:807-818.

    Not in our library10.1096/fj.07-9261com

  44. 44.

    Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326:140-144.

    Not in our library10.1126/science.1177221

  45. 45.

    Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 2010;11:453-465.

    Not in our library10.1016/j.cmet.2010.05.001

  46. 46.

    Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, Ocorr K, Ellisman MH, Bodmer R, Bier E, Karin M. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science. 2010;327:1223-1228.

    Not in our library10.1126/science.1182228

  47. 47.

    Katewa SD, Kapahi P. Role of TOR signaling in aging and related biological processes in Drosophila melanogaster. Exp Gerontol. 2011;46:382-390.

    Not in our library10.1016/j.exger.2010.11.036

  48. 48.

    Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61:1315-1322.

    Not in our library10.2337/db11-1300

  49. 49.

    de Magalhaes JP. A role for Ras signaling in modulating mammalian aging by the GH/IGF1 axis. Aging (Albany NY). 2011;3:336-337.

    Not in our library10.18632/aging.100309

  50. 50.
  51. 51.

    Demidenko ZN. Rapamycin for life: a step to immortality. Cell Cycle. 2011;10:4206.

    Not in our library10.4161/cc.10.24.18562

  52. 52.

    Passtoors WM, Beekman M, Deelen J, van der Breggen R, Maier AB, Guigas B, Derhovanessian E, van Heemst D, de Craen AJ, Gunn DA, Pawelec G, Slagboom PE. Gene expression analysis of mTOR pathway: association with human longevity. Aging Cell. 2012.

    Not in our library10.1111/acel.12015

  53. 53.

    Haselton A, Sharmin E, Schrader J, Sah M, Poon P, Fridell YW. Partial ablation of adult Drosophila insulin-producing neurons modulates glucose homeostasis and extends life span without insulin resistance. Cell Cycle. 2010;9:3063-3071.

    Not in our library10.4161/cc.9.15.12458

  54. 54.

    Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle. 2006;5:2087-2102.

    Not in our library10.4161/cc.5.18.3288

  55. 55.

    Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Disc Today. 2007;12:112-124.

    Not in our library10.1016/j.drudis.2006.12.008

  56. 56.

    Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19-24.

    Not in our library10.1038/ng1494

  57. 57.

    Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, Zhao YX, Zhang C, Zhang Y. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol. 2009;156:941-951.

    Not in our library10.1111/j.1476-5381.2008.00102.x

  58. 58.
  59. 59.

    Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol. 2012;181:1142-1146.

    Not in our library10.1016/j.ajpath.2012.06.024

  60. 60.

    Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011.

    Not in our library10.1016/j.ceb.2011.09.003

  61. 61.

    Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY). 2011;3:346-347.

    Not in our library10.18632/aging.100303

  62. 62.

    Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle. 2011;10:3447-3451.

    Not in our library10.4161/cc.10.20.17886

  63. 63.

    Lu MK, Gong XG, Guan KL. mTOR in podocyte function: is rapamycin good for diabetic nephropathy? Cell Cycle. 2011;10:3415-3416.

    Not in our library10.4161/cc.10.20.17686

  64. 64.

    Williamson DL. Normalizing a hyperactive mTOR initiates muscle growth during obesity. Aging (Albany NY). 2011;3:83-84.

    Not in our library10.18632/aging.100290

  65. 65.

    Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell. 2012;11:326-335.

    Not in our library10.1111/j.1474-9726.2011.00791.x

  66. 66.

    Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle. 2010;9:3151-3156.

    Not in our library10.4161/cc.9.16.13120

  67. 67.
  68. 68.

    Pani G. From growing to secreting: new roles for mTOR in aging cells. Cell Cycle. 2011;10:2450-2453.

    Not in our library10.4161/cc.10.15.16886

  69. 69.
  70. 70.

    Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. Embo J. 2011;30:1536-1548.

    Not in our library10.1038/emboj.2011.69

  71. 71.

    Laberge RM, Zhou L, Sarantos MR, Rodier F, Freund A, de Keizer PL, Liu S, Demaria M, Cong YS, Kapahi P, Desprez PY, Hughes RE, Campisi J. Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell. 2012;11:569-578.

    Not in our library10.1111/j.1474-9726.2012.00818.x

  72. 72.

    Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget. 2011;2:1203-1217.

    Not in our library10.18632/oncotarget.382

  73. 73.

    de Keizer PL, Laberge RM, Campisi J. p53: Pro-aging or pro-longevity? Aging (Albany NY). 2010;2:377-379.

    Not in our library10.18632/aging.100178

  74. 74.

    Blagosklonny MV. Cell senescence and hypermitogenic arrest. EMBO Rep. 2003;4:358-362.

    Not in our library10.1038/sj.embor.embor806

  75. 75.

    Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci. 2004;1028:1-13.

    Not in our library10.1196/annals.1322.001

  76. 76.

    Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C. Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des. 2006;12:161-3171.

    Not in our library10.2174/138161206777947470

  77. 77.

    Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle. 2011;10:2059-2063.

    Not in our library10.4161/cc.10.13.16233

  78. 78.

    Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer”;. Cell Cycle. 2011;10:2440-2449.

    Not in our library10.4161/cc.10.15.16870

  79. 79.

    Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging (Albany NY). 2010;2:361-368.

    Not in our library10.18632/aging.100155

  80. 80.

    Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3:533-542.

    Not in our library10.18632/aging.100327

  81. 81.

    Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169-176.

    Not in our library10.1111/j.1474-9728.2004.00101.x

  82. 82.

    Wanner SP, Garami A, Pakai E, Oliveira DL, Gavva NR, Coimbra CC, Romanovsky AA. Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle. 2012;11:343-349.

    Not in our library10.4161/cc.11.2.18772

  83. 83.

    Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet. 2001;358:472-473.

    Not in our library10.1016/s0140-6736(01)05633-1

  84. 84.

    Gadalla SM, Cawthon R, Giri N, Alter BP, Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany NY). 2010;2:867-874.

    Not in our library10.18632/aging.100235

  85. 85.

    Njajou OT, Hsueh WC, Blackburn EH, Newman AB, Wu SH, Li R, Simonsick EM, Harris TM, Cummings SR, Cawthon RM. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci. 2009;64:860-864.

    Not in our library10.1093/gerona/glp061

  86. 86.

    Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312-17315.

    Not in our library10.1073/pnas.0407162101

  87. 87.
  88. 88.

    Gramatges MM, Bertuch AA. Measuring relative telomere length: is tissue an issue? Aging (Albany NY). 2010;2:756-757.

    Not in our library10.18632/aging.100236

  89. 89.

    Jemielity S, Kimura M, Parker KM, Parker JD, Cao X, Aviv A, Keller L. Short telomeres in short-lived males: what are the molecular and evolutionary causes? Aging Cell. 2007;6:225-233.

    Not in our library10.1111/j.1474-9726.2007.00279.x

  90. 90.

    Bekaert S, De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, Segers P, Cooman L, Van Damme P, Cassiman P, Van Criekinge W, Verdonck P, De Backer GG, Gillebert TC, Van Oostveldt P. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007;6:639-647.

    Not in our library10.1111/j.1474-9726.2007.00321.x

  91. 91.

    Kuhlow D, Florian S, von Figura G, Weimer S, Schulz N, Petzke KJ, Zarse K, Pfeiffer AF, Rudolph KL, Ristow M. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging (Albany NY). 2010;2:650-658.

    Not in our library10.18632/aging.100200

  92. 92.

    Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, Cummings JL, Effros RB. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging. 2003;24:77-84.

    Not in our library10.1016/s0197-4580(02)00043-x

  93. 93.

    Ishikawa N, Nakamura K, Izumiyama-Shimomura N, Aida J, Ishii A, Goto M, Ishikawa Y, Asaka R, Matsuura M, Hatamochi A, Kuroiwa M, Takubo K. Accelerated in vivo epidermal telomere loss in Werner syndrome. Aging (Albany NY). 2011;3:417-429.

    Not in our library10.18632/aging.100315

  94. 94.

    Gems DH, de la Guardia YI. Alternative Perspectives on Aging in C. elegans: Reactive Oxygen Species or Hyperfunction? Antioxid Redox Signal. 2012.

    Not in our library10.1089/ars.2012.4840

  95. 95.

    Gems D, Partridge L. Genetics of Longevity in Model Organisms: Debates and Paradigm Shifts. Annu Rev Physiol. 2012.

    Not in our library10.1146/annurev-physiol-030212-183712

  96. 96.

    Blagosklonny MV. Rapamycin and quasi-programmed aging: Four years later. Cell Cycle. 2010;9:1859-1862.

    Not in our library10.4161/cc.9.10.11872

  97. 97.

    Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Disc Today. 2007;12:218-224.

    Not in our library10.1016/j.drudis.2007.01.004

  98. 98.

    Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, Lithgow GJ, Kapahi P. Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell. 2007;6:111-119.

    Not in our library10.1111/j.1474-9726.2006.00266.x

  99. 99.

    Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 2007;6:95-110.

    Not in our library10.1111/j.1474-9726.2006.00267.x

  100. 100.

    Mehta R, Chandler-Brown D, Ramos FJ, Shamieh LS, Kaeberlein M. Regulation of mRNA translation as a conserved mechanism of longevity control. Adv Exp Med Biol. 2010;694:14-29.

    Not in our library10.1007/978-1-4419-7002-2_2

  101. 101.

    Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011;2:1352-1367.

    Not in our library10.18632/oncotarget.432

  102. 102.
  103. 103.
  104. 104.

    Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107:1028-1033.

    Not in our library10.1016/j.amjcard.2010.11.026

  105. 105.

    Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle. 2011;10:1363-1369.

    Not in our library10.4161/cc.10.9.15444

  106. 106.

    Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res. 1995;77:1040-1052.

    Not in our library10.1161/01.res.77.6.1040

  107. 107.

    Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010;2:760-774.

    Not in our library10.18632/aging.100230

  108. 108.

    Demidenko ZN. Chronological lifespan in stationary culture: from yeast to human cells. Aging (Albany NY). 2011;3:1041-1042.

    Not in our library10.18632/aging.100406

  109. 109.
  110. 110.

    Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010;9:188-197.

    Not in our library10.4161/cc.9.1.10407

  111. 111.

    Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am J Med Sci. 2008;336:241-247.

    Not in our library10.1097/maj.0b013e31816250e6

  112. 112.

    Menendez JA, Cufi S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY). 2011;3:348-362.

    Not in our library10.18632/aging.100316

  113. 113.

    Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandezr E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature. 2009;460:392-396.

    Not in our library10.1038/nature08221

  114. 114.

    Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66:191-201.

    Not in our library10.1093/gerona/glq178

  115. 115.

    Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:4230-4236.

    Not in our library10.4161/cc.10.24.18486

  116. 116.

    Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;176:2092-2097.

    Not in our library10.2353/ajpath.2010.091050

  117. 117.

    Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA. Rapamycin slows aging in mice. Aging Cell. 2012;11:675-682.

    Not in our library10.1111/j.1474-9726.2012.00832.x

  118. 118.

    Khanna A, Kapahi P. Rapamycin: killing two birds with one stone. Aging (Albany NY). 2011;3:1043-1044.

    Not in our library10.18632/aging.100405

  119. 119.

    Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY). 2011;3:1039-1040.

    Not in our library10.18632/aging.100401

  120. 120.

    Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: Preliminary proposal. Cell Cycle. 2010;9:4788-4794.

    Not in our library10.4161/cc.9.24.14360

  121. 121.

    Blagosklonny MV. How to save Medicare: the anti-aging remedy. Aging (Albany NY). 2012;4:547-552.

    Not in our library10.18632/aging.100479

  122. 122.

    Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY). 2011;3:1130-1141.

    Not in our library10.18632/aging.100422

  123. 123.

    Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle. 2009;8:4112-4118.

    Not in our library10.4161/cc.8.24.10215

  124. 124.

    Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle. 2012;11:4642-4649.

    Not in our library10.4161/cc.22937

  125. 125.

    Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, Coppe JP, Campeau E, Beausejour CM, Kim SH, Davalos AR, Campisi J. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci. 2011;124:68-81.

    Not in our library10.1242/jcs.071340

  126. 126.

    Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973-979.

    Not in our library10.1038/ncb1909

  127. 127.

    Blagosklonny MV. mTOR-driven aging: speeding car without brakes. Cell Cycle. 2009;8:4055-4059.

    Not in our library10.4161/cc.8.24.10310

  128. 128.

    Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY). 2010;2:265-273.

    Not in our library10.18632/aging.100149

  129. 129.

    Blagosklonny MV. Rapamycin-induced glucose intolerance: Hunger or starvation diabetes. Cell Cycle. 2011;10:4217-4224.

    Not in our library10.4161/cc.10.24.18595

  130. 130.

    Blandino-Rosano M, Chen AY, Scheys JO, Alejandro EU, Gould AP, Taranukha T, Elghazi L, Cras-Meneur C, Bernal-Mizrachi E. mTORC1 signaling and regulation of pancreatic beta-cell mass. Cell Cycle. 2012;11.

    Not in our library10.4161/cc.20036

  131. 131.

    Partridge L, Gems D. Mechanisms of ageing: public or private? Nat Rev Genet. 2002;3:165-175.

    Not in our library10.1038/nrg753

  132. 132.

    Bishop NA, Guarente L. Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature. 2007;447:545-549.

    Not in our library10.1038/nature05904

  133. 133.

    Krakauer T, Buckley M, Issaq HJ, Fox SD. Rapamycin Protects Mice from Staphylococcal Enterotoxin B-Induced Toxic Shock and Blocks Cytokine Release In vitro and In Vivo. Antimicrob Agents Chemother. 2010.

    Not in our library10.1128/aac.01015-09

  134. 134.

    Weiss G, Skurnick JH, Goldsmith LT, Santoro NF, Park SJ. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA. 2004;292:2991-2996.

    Not in our library10.1001/jama.292.24.2991

  135. 135.

    Prior JC. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine. 2005;26:297-300.

    Not in our library10.1385/endo:26:3:297

  136. 136.

    Horiuchi S. Postmenopausal acceleration of age-related mortality increase. J Gerontol A Biol Sci Med Sci. 1997;52:B78-92.

    Not in our library10.1093/gerona/52a.1.b78

  137. 137.

    Heys KR, Cram SL, Truscott RJ. Massive increase in the stiffness of the human lens nucleus with age: the basis for presbyopia? Mol Vis. 2004;10:956-963.

    Not in our library

  138. 138.

    Truscott RJ. Presbyopia. Emerging from a blur towards an understanding of the molecular basis for this most common eye condition. Exp Eye Res. 2009;88:241-247.

    Not in our library10.1016/j.exer.2008.07.003

  139. 139.

    Wendt M, Croft MA, McDonald J, Kaufman PL, Glasser A. Lens diameter and thickness as a function of age and pharmacologically stimulated accommodation in rhesus monkeys. Exp Eye Res. 2008;86:746-752.

    Not in our library10.1016/j.exer.2008.01.022

  140. 140.

    Rosen AM, Denham DB, Fernandez V, Borja D, Ho A, Manns F, Parel JM, Augusteyn RC. In vitro dimensions and curvatures of human lenses. Vision Res. 2006;46:1002-1009.

    Not in our library10.1016/j.visres.2005.10.019

  141. 141.

    McGinty SJ, Truscott RJ. Presbyopia: the first stage of nuclear cataract? Ophthalmic Res. 2006;38:137-148.

    Not in our library10.1159/000090645

  142. 142.

    Blagosklonny MV. Program-like aging and mitochondria: instead of random damage by free radicals. J Cell Biochem. 2007;102:1389-1399.

    Not in our library10.1002/jcb.21602

  143. 143.

    Michno K, van de Hoef D, Wu H, Boulianne GL. Modeling age-related diseases in Drosophila: can this fly? Curr Top Dev Biol. 2005;71:199-223.

    Not in our library10.1016/s0070-2153(05)71006-1

  144. 144.

    Nelson B, Nishimura S, Kanuka H, Kuranaga E, Inoue M, Hori G, Nakahara H, Miura M. Isolation of gene sets affected specifically by polyglutamine expression: implication of the TOR signaling pathway in neurodegeneration. Cell Death Differ. 2005;12:1115-1123.

    Not in our library10.1038/sj.cdd.4401635

  145. 145.

    Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol. 2006;16:230-241.

    Not in our library10.1016/j.cub.2005.12.042

  146. 146.

    Chaudhuri A, Bowling K, Funderburk C, Lawal H, Inamdar A, Wang Z, O'Donnell JM. Interaction of genetic and environmental factors in a Drosophila parkinsonism model. J Neurosci. 2007;27:2457-2467.

    Not in our library10.1523/jneurosci.4239-06.2007

  147. 147.

    Birse RT, Choi J, Reardon K, Rodriguez J, Graham S, Diop S, Ocorr K, Bodmer R, Oldham S. High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila. Cell Metab. 2010;12:533-544.

    Not in our library10.1016/j.cmet.2010.09.014

  148. 148.

    Wessells R, Fitzgerald E, Piazza N, Ocorr K, Morley S, Davies C, Lim HY, Elmen L, Hayes M, Oldham S, Bodmer R. d4eBP acts downstream of both dTOR and dFoxo to modulate cardiac functional aging in Drosophila. Aging Cell. 2009;8:542-552.

    Not in our library10.1111/j.1474-9726.2009.00504.x

  149. 149.

    Teleman AA, Ratzenbock I, Oldham S. Drosophila: a model for understanding obesity and diabetic complications. Exp Clin Endocrinol Diabetes. 2012;120:184-185.

    Not in our library10.1055/s-0032-1304566

  150. 150.

    Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R, Bodmer R, Oldham SM. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab. 2006;4:133-142.

    Not in our library10.1016/j.cmet.2006.05.013

  151. 151.

    Broughton SJ, Piper MD, Ikeya T, Bass TM, Jacobson J, Driege Y, Martinez P, Hafen E, Withers DJ, Leevers SJ, Partridge L. Longer lifespan, altered metabolism, and stress resistance in Drosophila from ablation of cells making insulin-like ligands. Proc Natl Acad Sci U S A. 2005;102:3105-3110.

    Not in our library10.1073/pnas.0405775102

  152. 152.

    Oldham S. Obesity and nutrient sensing TOR pathway in flies and vertebrates: Functional conservation of genetic mechanisms. Trends Endocrinol Metab. 2011;22:45-52.

    Not in our library10.1016/j.tem.2010.11.002

  153. 153.

    Diop SB, Bodmer R. Drosophila as a model to study the genetic mechanisms of obesity-associated heart dysfunction. J Cell Mol Med. 2012;16:966-971.

    Not in our library10.1111/j.1582-4934.2012.01522.x

  154. 154.

    Morris SN, Coogan C, Chamseddin K, Fernandez-Kim SO, Kolli S, Keller JN, Bauer JH. Development of diet-induced insulin resistance in adult Drosophila melanogaster. Biochim Biophys Acta. 2012;1822:1230-1237.

    Not in our library10.1016/j.bbadis.2012.04.012

  155. 155.

    Haselton AT, Fridell YW. Adult Drosophila melanogaster as a model for the study of glucose homeostasis. Aging (Albany NY). 2010;2:523-526.

    Not in our library10.18632/aging.100185

  156. 156.

    Musselman LP, Fink JL, Narzinski K, Ramachandran PV, Hathiramani SS, Cagan RL, Baranski TJ. A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila. Dis Model Mech. 2011;4:842-849.

    Not in our library10.1242/dmm.007948

  157. 157.

    Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R, Bodmer R, Oldham SM. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab. 2006;4:133-142.

    Not in our library10.1016/j.cmet.2006.05.013

  158. 158.

    Biteau B, Karpac J, Hwangbo D, Jasper H. Regulation of Drosophila lifespan by JNK signaling. Exp Gerontol. 2011;46:349-354.

    Not in our library10.1016/j.exger.2010.11.003

  159. 159.

    Jasper H, Kennedy BK. Niche science: the aging stem cell. Cell Cycle. 2012;11:2959-2960.

    Not in our library10.4161/cc.21558

  160. 160.
  161. 161.

    Biteau B, Hochmuth CE, Jasper H. JNK activity in somatic stem cells causes loss of tissue homeostasis in the aging Drosophila gut. Cell Stem Cell. 2008;3:442-455.

    Not in our library10.1016/j.stem.2008.07.024

  162. 162.

    Moskalev A, Shaposhnikov M. Pharmacological inhibition of NF-kappaB prolongs lifespan of Drosophila melanogaster. Aging (Albany NY). 2011;3:391-394.

    Not in our library10.18632/aging.100314

  163. 163.

    Brignull HR, Morley JF, Garcia SM, Morimoto RI. Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol. 2006;412:256-282.

    Not in our library10.1016/s0076-6879(06)12016-9

  164. 164.

    Vosseller K. O-GlcNAc and aging: C. elegans as a genetic model to test O-GlcNAc roles in type II diabetic insulin resistance. Aging (Albany NY). 2010;2:749-751.

    Not in our library10.18632/aging.100225

  165. 165.

    Rahman MM, Stuchlick O, El-Karim EG, Stuart R, Kipreos ET, Wells L. Intracellular protein glycosylation modulates insulin mediated lifespan in C.elegans. Aging (Albany NY). 2010;2:678-690.

    Not in our library10.18632/aging.100208

  166. 166.

    Williams TW, Dumas KJ, Hu PJ. EAK proteins: novel conserved regulators of C. elegans lifespan. Aging (Albany NY). 2010;2:742-747.

    Not in our library10.18632/aging.100214

  167. 167.
  168. 168.

    Solari F. CeKlotho opens a new road for investigation in worm aging. Aging (Albany NY). 2010;2:539-540.

    Not in our library10.18632/aging.100198

  169. 169.
  170. 170.

    Hulbert AJ. Longevity, lipids and C. elegans. Aging (Albany NY). 2011;3:81-82.

    Not in our library10.18632/aging.100288

  171. 171.

    Chateau MT, Araiz C, Descamps S, Galas S. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging (Albany NY). 2010;2:567-581.

    Not in our library10.18632/aging.100195

  172. 172.

    Rongo C. Epidermal growth factor and aging: a signaling molecule reveals a new eye opening function. Aging (Albany NY). 2011;3:896-905.

    Not in our library10.18632/aging.100384

  173. 173.

    Alavez S, Lithgow GJ. Pharmacological maintenance of protein homeostasis could postpone age-related disease. Aging Cell. 2012;11:187-191.

    Not in our library10.1111/j.1474-9726.2012.00789.x

  174. 174.

    Lithgow GJ. Does anti-aging equal anti-microbial? Sci Aging Knowledge Environ. 2003;2003:PE16.

    Not in our library10.1126/sageke.2003.25.pe16

  175. 175.

    Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem. 2005;280:2282-2293.

    Not in our library10.1074/jbc.m412179200

  176. 176.

    Elghazi L, Balcazar N, Blandino-Rosano M, Cras-Meneur C, Fatrai S, Gould AP, Chi MM, Moley KH, Bernal-Mizrachi E. Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells. Diabetes. 2010;59:2390-2399.

    Not in our library10.2337/db09-0851

  177. 177.

    Rachdi L, Balcazar N, Osorio-Duque F, Elghazi L, Weiss A, Gould A, Chang-Chen KJ, Gambello MJ, Bernal-Mizrachi E. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci U S A. 2008;105:9250-9255.

    Not in our library10.1073/pnas.0803047105

  178. 178.

    Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, Matsuda T, Takeda A, Inoue T, Shibutani Y, Koyanagi M, Uchida T, Inoue M, Hino O, Kasuga M, Noda T. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol. 2008;28:2971-2979.

    Not in our library10.1128/mcb.01695-07

  179. 179.

    Bonda DJ, Evans TA, Santocanale C, Llosa JC, Vina J, Bajic VP, Castellani RJ, Siedlak SL, Perry G, Smith MA, Lee HG. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY). 2009;1:382-388.

    Not in our library10.18632/aging.100044

  180. 180.

    Frade JM. Unscheduled re-entry into the cell cycle induced by NGF precedes cell death in nascent retinal neurones. J Cell Sci. 2000;113(Pt 7):1139-1148.

    Not in our library10.1242/jcs.113.7.1139

  181. 181.

    Song B, Davis K, Liu XS, Lee HG, Smith M, Liu X. Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease. Aging (Albany NY). 2011;3:846-851.

    Not in our library10.18632/aging.100382

  182. 182.

    Frade JM, Lopez-Sanchez N. A novel hypothesis for Alzheimer disease based on neuronal tetraploidy induced by p75 (NTR). Cell Cycle. 2010;9:1934-1941.

    Not in our library10.4161/cc.9.10.11582

  183. 183.

    Futatsugi A, Utreras E, Rudrabhatla P, Jaffe H, Pant HC, Kulkarni AB. Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons. Cell Cycle. 2012;11:1603-1610.

    Not in our library10.4161/cc.20009

  184. 184.

    Stanga S, Lanni C, Govoni S, Uberti D, D'Orazi G, Racchi M. Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging (Albany NY). 2010;2:545-554.

    Not in our library10.18632/aging.100205

  185. 185.

    Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle. 2009;8:1003-1006.

    Not in our library10.4161/cc.8.7.8045

  186. 186.

    Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009;5:279-289.

    Not in our library10.1016/j.stem.2009.06.017

  187. 187.

    Ratajczak MZ, Shin DM, Ratajczak J, Kucia M, Bartke A. A novel insight into aging: are there pluripotent very small embryonic-like stem cells (VSELs) in adult tissues overtime depleted in an Igf-1-dependent manner? Aging (Albany NY). 2010;2:875-883.

    Not in our library10.18632/aging.100231

  188. 188.

    Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, HŠmŠlŠinen T, Peng SL, Lan ZJ, Cooney AJ, Huhtaniemi I, Liu K. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319:611-613.

    Not in our library10.1126/science.1152257

  189. 189.

    Reddy P, Adhikari D, Zheng W, Liang S, Hamalainen T, Tohonen V, Ogawa W, Noda T, Volarevic S, Huhtaniemi I, Liu K. PDK1 signaling in oocytes controls reproductive aging and lifespan by manipulating the survival of primordial follicles. Hum Mol Genet. 2009;18:2813-2824.

    Not in our library10.1093/hmg/ddp217

  190. 190.

    Adhikari D, Liu K. mTOR signaling in the control of activation of primordial follicles. Cell Cycle. 2010;9:1673-1674.

    Not in our library10.4161/cc.9.9.11626

  191. 191.

    Adhikari D, Flohr G, Gorre N, Shen Y, Yang H, Lundin E, Lan Z, Gambello MJ, Liu K. Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles. Mol Hum Reprod. 2009;15:765-770.

    Not in our library10.1093/molehr/gap092

  192. 192.

    Blagosklonny MV. Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells. Rejuvenation Res. 2008;11:801-808.

    Not in our library10.1089/rej.2008.0722

  193. 193.

    Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY). 2011;3:1078-1091.

    Not in our library10.18632/aging.100402

  194. 194.

    Fabrizio P, Wei M. Conserved role of medium acidification in chronological senescence of yeast and mammalian cells. Aging (Albany NY). 2011;3:1127-1129.

    Not in our library10.18632/aging.100412

  195. 195.

    Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433-442.

    Not in our library10.1093/hmg/ddi458

  196. 196.

    Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol. 2006;76:89-101.

    Not in our library10.1016/s0070-2153(06)76003-3

  197. 197.

    Sarkar S, Rubinsztein DC. Huntington's disease: degradation of mutant huntingtin by autophagy. Febs J. 2008;275:4263-4270.

    Not in our library10.1111/j.1742-4658.2008.06562.x

  198. 198.

    Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related protein-pathies. Cell Death Differ. 2009;16:46-56.

    Not in our library10.1038/cdd.2008.110

  199. 199.

    Menzies FM, Rubinsztein DC. Broadening the therapeutic scope for rapamycin treatment. Autophagy. 2010;6:286-287.

    Not in our library10.4161/auto.6.2.11078

  200. 200.

    Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011;3:89ra58.

    Not in our library10.1126/scitranslmed.3002346

  201. 201.

    Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010;115:1406-1415.

    Not in our library10.1182/blood-2009-06-229443

  202. 202.

    Hay N. Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. 2011;1813:1965-1970.

    Not in our library10.1016/j.bbamcr.2011.03.013

  203. 203.
  204. 204.

    Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Dis. 2010;1:e12.

    Not in our library10.1038/cddis.2009.17

  205. 205.

    Sheaffer KL, Updike DL, Mango SE. The Target of Rapamycin pathway antagonizes pha-4/FoxA to control development and aging. Curr Biol. 2008;18:1355-1364.

    Not in our library10.1016/j.cub.2008.07.097

  206. 206.

    Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell. 2010;18:592-604.

    Not in our library10.1016/j.devcel.2010.03.008

  207. 207.

    Oh SW, Mukhopadhyay A, Svrzikapa N, Jiang F, Davis RJ, Tissenbaum HA. JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor/DAF-16. Proc Natl Acad Sci U S A. 2005;102:4494-4499.

    Not in our library10.1073/pnas.0500749102

  208. 208.

    Balasubramanian P, Longo VD. Linking Klotho, Nrf2, MAP kinases and aging. Aging (Albany NY). 2010;2:632-633.

    Not in our library10.18632/aging.100219

  209. 209.

    Belgardt BF, Mauer J, Bruning JC. Novel roles for JNK1 in metabolism. Aging (Albany NY). 2010;2:621-626.

    Not in our library10.18632/aging.100192

  210. 210.

    Spencer NF, Poynter ME, Im SY, Daynes RA. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol. 1997;9:1581-1588.

    Not in our library10.1093/intimm/9.10.1581

  211. 211.

    Vaughan S, Jat PS. Deciphering the role of nuclear factor-kappaB in cellular senescence. Aging (Albany NY). 2011;3:913-919.

    Not in our library10.18632/aging.100390

  212. 212.

    Tilstra JS, Robinson AR, Wang J, Gregg SQ, Clauson CL, Reay DP, Nasto LA, St Croix CM, Usas A, Vo N, Huard J, Clemens PR, Stolz DB, Guttridge DC, Watkins SC, Garinis GA, et al. NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest. 122;2601-2612.

    Not in our library10.1172/jci45785

  213. 213.

    Dreesen O, Stewart CL. Accelerated aging syndromes, are they relevant to normal human aging? Aging (Albany NY). 2011;3:889-895.

    Not in our library10.18632/aging.100383

  214. 214.

    Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY). 2011;3:1051-1062.

    Not in our library10.18632/aging.100411

  215. 215.

    Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S. PI3Kalpha inhibitors that inhibit metastasis. Oncotarget. 2010;1:339-348.

    Not in our library10.18632/oncotarget.166

  216. 216.

    Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2011;2:833-849.

    Not in our library10.18632/oncotarget.346

  217. 217.

    Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430.

    Not in our library10.1038/nature04869

  218. 218.

    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.

    Not in our library10.1016/j.ccr.2007.05.008

  219. 219.

    Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle. 2011;10:1050-1058.

    Not in our library10.4161/cc.10.7.15230

  220. 220.

    Bhatia B, Nahle Z, Kenney AM. Double trouble: when sonic hedgehog signaling meets TSC inactivation. Cell Cycle. 2010;9:456-459.

    Not in our library10.4161/cc.9.3.10532

  221. 221.

    Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget. 2011;2:435-447.

    Not in our library10.18632/oncotarget.285

  222. 222.

    Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2011;2:1314-1321.

    Not in our library10.18632/oncotarget.409

  223. 223.

    Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget. 2011;2:538-550.

    Not in our library10.18632/oncotarget.302

  224. 224.

    Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle. 2011;10:2115-2120.

    Not in our library10.4161/cc.10.13.16244

  225. 225.
  226. 226.
  227. 227.

    Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10:868-880.

    Not in our library10.1038/nrd3531

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.